Tiziana Life Sciences (TLSA) said Tuesday the ALS Association has approved its grant application for funding a 20-participant clinical study of two doses of its intranasal foralumab candidate to treat amyotrophic lateral sclerosis.
The company said it will receive the funding as part of the Hoffman ALS Clinical Trial Awards Program.
Terms of the funding weren't disclosed.
Tiziana said it is also evaluating intranasal foralumab in a phase 2a multicenter, dose-ranging study in patients with non-active secondary progressive multiple sclerosis.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。